Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Low success rates during drug development are due, in part, to the difficulty of defining drug mechanism‐of‐action and molecular markers of therapeutic activity. Here, we integrated 199,219 drug sensitivity measurements for 397 unique anti‐cancer drugs with genome‐wide CRISPR loss‐of‐function screen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Emanuel, Segura‐Cabrera, Aldo, Pacini, Clare, Picco, Gabriele, Behan, Fiona M, Jaaks, Patricia, Coker, Elizabeth A, van der Meer, Donny, Barthorpe, Andrew, Lightfoot, Howard, Mironenko, Tatiana, Beck, Alexandra, Richardson, Laura, Yang, Wanjuan, Lleshi, Ermira, Hall, James, Tolley, Charlotte, Hall, Caitlin, Mali, Iman, Thomas, Frances, Morris, James, Leach, Andrew R, Lynch, James T, Sidders, Ben, Crafter, Claire, Iorio, Francesco, Fawell, Stephen, Garnett, Mathew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336273/
https://www.ncbi.nlm.nih.gov/pubmed/32627965
http://dx.doi.org/10.15252/msb.20199405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336273/
https://www.ncbi.nlm.nih.gov/pubmed/32627965
http://dx.doi.org/10.15252/msb.20199405

Ejemplares similares